‘We’re turning aging research into a therapeutic category’
Rejuvenate Bio CEO on why sourcing gene therapy targets from aging research may hold the key to treating many chronic diseases.
It’s been an interesting year for Harvard spin-out Rejuvenate Bio, which is targeting age-related chronic diseases with gene therapy and cellular reprogramming approaches. Earlier this year, the company produced some interesting preclinical data showing that its cellular reprogramming therapy improved healthspan in older mice and increased their remaining lifespan by 109% compared with control mice.

And, having recently revealed that its gene therapy candidate delivered promising preclinical results in the treatment of a rare heart condition, Rejuvenate Bio also made progress in its animal health pipeline, with a gene therapy for heart disease in dogs demonstrating positive results in a pilot study.

Longevity.Technology: Rejuvenate Bio emerged from the Harvard lab of renowned geneticist George Church in 2018, with an approach based on the fundamental idea that aging is the single largest risk factor for many chronic conditions. With programs in both human and animal health, the company is developing multiple gene therapies, each with the potential to impact multiple age-related diseases. To learn more, we caught up with CEO Daniel Oliver, who co-founded the Rejuvenate Bio along with Church and postdoctoral fellow Noah Davidsohn.

Rather than addressing age-related diseases individually, Rejuvenate Bio is focused on the “interconnectedness” of the aging process itself – particularly those genes that have been validated to play a key role in aging and longevity.

‘We’re turning aging research into a therapeutic category’